Close Menu

NEW YORK (360Dx) – While known primarily as a blood plasma-based products firm, Grifols has progressively built up its diagnostics business. Now, those investments are showing up in both the firm's top and bottom lines.

On Friday, the company reported revenues in its diagnostics division rose by 11 percent during the first half of 2017 to €351.1 million ($410.8 million), compared to €316.8 in the first half of 2016. For the second quarter of 2017, diagnostic sales were up 16 percent year over year, the firm said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.